Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease

Neurological Sciences

Volumn 30, Issue 4, 2009, Pages 301-305

  Djaldetti, Ruth ^a   Treves, Therese A ^a,c   Ziv, Ilan ^a,c   Melamed, Eldad ^a,c   Lampl, Yair ^b   Lorberboym, Mordechai ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

123I FP CIT; Disease severity; Parkinson's disease; Prediction

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FP CIT I 123; IOFLUPANE; LEVODOPA; RADIOPHARMACEUTICAL AGENT; ROPINIROLE; SELEGILINE; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRADYKINESIA; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG UPTAKE; FOLLOW UP; HUMAN; MUSCLE RIGIDITY; PARKINSON DISEASE; PREDICTION; PUTAMEN; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; UNIFIED PARKINSON DISEASE RATING SCALE; DYSKINESIA; FEMALE; MALE; MIDDLE AGED; NEOSTRIATUM; NEUROLOGIC EXAMINATION; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; DYSKINESIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE RIGIDITY; NEOSTRIATUM; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PUTAMEN; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 67650970263     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-009-0100-4     Document Type: Article

References (23)

1. 123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46:231-237
2. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 62:133-140
3. Mozley PD, Schneider JS, Acton PD, Plossl K, Stern MB, Siderowf A et al (2000) Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 41:584-589
4. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC (2003) [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 74:294-298
5. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
6. Marshall V, Grosset DG (2003) Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord 18(Suppl 7):S22-S27
7. 123 I-IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology 52:1422-1426
8. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 45:1688-1693
9. 123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 21:510-514
10. Brooks DJ (1993) Functional imaging in relation to parkinsonian syndromes. J Neurol 115:1-17
11. 123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15:1158-1167
12. Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T et al (2002) Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17:303-312
13. Morrish PK, Sawle GV, Brooks DJ (1996) Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain 119:2097-2103
14. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38:589-598
15. 123 I]IPT and single-photon emission tomography. Eur J Nucl Med 24:415-421
16. 123I-FP-CIT SPECT striatal uptake. Mov Disord 15:692-698
17. 123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57:2089-2094
18. Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T (2003) Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord 18:1266-1272
19. Dujardin K, Defebvre L, Duhamel A, Lecouffe P, Rogelet P, Steinling M et al (2004) Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J Neurol 251:1383-1392
20. Bruck A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO (2006) Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: A two-year follow-up study. Mov Disord 21:958-963
21. 123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50:9-24
22. Spiegel J, Hellwig D, Samnick S, Jost W, Möllers MO, Fassbenger K et al (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J Neural Transm 114:331-335
23. 123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. Neuroreport 18:1499-1502